Celon Pharma S.A.  announces robust and positive Phase 2 clinical trial results for its PDE10A inhibitor (CPL’36), a novel, oral, once-daily medication for the treatment of Levodopa-Induced Dyskinesia (LID) in Parkinson’s disease. The study met its primary endpoint and many of its secondary endpoints. CPL’36 demonstrated robust and consistent efficacy across all utilized scales measuring improvement in treatment of LID in Parkinson’s disease. The effect size was large and clinically meaningful. CPL’36 was previously investigated as a potential treatment for schizophrenia and demonstrated positive Phase 2 results that were reported in July 2024.

“I am very pleased that the clinical effect of CPL'36 has now been confirmed also for the treatment of LID dyskinesia in Parkinson's disease. The results are unequivocally positive, clinically meaningful, and statistically significant, and have met all the criteria we prespecified. We believe that CPL’36 has potential to significantly contribute to the expansion and advancement of the global market for Parkinson's disease pharmacotherapy, and to provide sizeable clinical benefits to LID patients who are underserved by current treatments.”- stated Maciej Wieczorek, Ph.D., CEO of Celon Pharma S.A.

“It is important to note that CPL’36 has a unique pharmacodynamic profile, characterized by rapid enzyme dissociation, which distinguishes it from other PDE10A inhibitors. We believe this attribute is key to the positive clinical outcomes we have generated thus far," said Joanna Sierzputowska-Prarat, Main Clinical Neuropsychiatry Lead at Celon Pharma S.A.